The Lund-based inhaler experts Iconovo are on the front lines of the fight against asthma, and they recently announced a new partnership dedicated to the development of ICOres budesonide/formoterol, the generic for AstraZeneca’s Symbicort, which is currently on the market for the treatment of asthma. BioStock was able to talk with Iconovo’s CEO Johan Wäborg to discuss the implications of the partnership and what it means for the ongoing battle against asthma.

Read more